Valsartan class of drug
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Valsartan: A Comprehensive Overview
Introduction to Valsartan and Its Drug Class
Valsartan is a medication that belongs to the class of drugs known as Angiotensin II Receptor Blockers (ARBs). These drugs are primarily used to manage hypertension (high blood pressure) and heart failure. Valsartan works by selectively inhibiting the actions of angiotensin II at the AT1 receptor subtype, which is responsible for most of the known effects of angiotensin II, including vasoconstriction and aldosterone secretion.
Therapeutic Uses of Valsartan
Hypertension Management
Valsartan is widely used in the treatment of mild to moderate essential hypertension. Clinical trials have demonstrated that valsartan is as effective as other antihypertensive agents such as losartan, lisinopril, enalapril, amlodipine, and hydrochlorothiazide. It is particularly beneficial for patients who experience persistent cough with ACE inhibitors, as valsartan has a significantly lower incidence of this side effect.
Heart Failure Treatment
Valsartan is also effective in managing heart failure. In a large-scale study involving 5010 patients with heart failure, valsartan significantly reduced the combined endpoint of mortality and morbidity, primarily by decreasing the number of hospitalizations for heart failure. The drug also improved clinical signs and symptoms, ejection fraction, and quality of life in these patients.
Post-Myocardial Infarction and Chronic Kidney Disease
Valsartan has shown safety and efficacy in patients with post-myocardial infarction and chronic kidney disease. It is well-tolerated in these populations, although serum potassium levels need to be monitored closely. The drug does not adversely affect glucose and lipid metabolism in diabetic hypertensive patients and even improves these parameters.
Safety and Tolerability
Valsartan is generally considered safe and well-tolerated. The most frequently reported adverse events include malaise, fatigue, dizziness, headache, and nausea, with incidences similar to those observed with placebo. When combined with hydrochlorothiazide, valsartan counteracts the adverse metabolic effects of the diuretic and reduces ankle edema formation when combined with amlodipine.
Valsartan in Combination Therapies
Sacubitril/Valsartan (ARNI)
Sacubitril/valsartan, marketed as LCZ696, is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI). This combination provides dual inhibition of neprilysin and the angiotensin (AT1) receptor, offering superior outcomes compared to ACE inhibitors in heart failure patients. Sacubitril/valsartan has shown promise in reducing central aortic systolic pressure and nocturnal blood pressure, making it a potential therapeutic agent for age-related hypertension phenotypes.
Potential Antiarrhythmic Effects
Recent studies suggest that sacubitril/valsartan may also have antiarrhythmic properties. In the PARADIGM-HF trial, the drug reduced the risk of sudden death and heart failure hospitalization, although it did not significantly affect the incidence of atrial fibrillation.
Impact of Drug Shortages
A major recall and shortage of valsartan in Canada in July 2018 led to a significant decrease in its use, with cascading effects on the use of other ARBs and ACE inhibitors. This highlights the need for improved policy strategies to address drug shortages and mitigate their effects on patient care.
Conclusion
Valsartan is a versatile and effective ARB used in the management of hypertension, heart failure, and post-myocardial infarction. Its combination with sacubitril as an ARNI offers additional benefits, particularly in heart failure management. Despite its safety and efficacy, the impact of drug shortages underscores the importance of robust healthcare policies to ensure consistent drug availability.
Sources and full results
Most relevant research papers on this topic